High levels of TRAIL-R3 and CCR-2 expression in TEpCs identified early breast cancer patients with poor outcomes, including a higher risk of metastasis and shorter DFS, MFS, and OS and represent new independent prognostic factors that may also be suitable therapeutic targets. This evidence concerns the gene CCR2 and breast carcinoma.